All Insight, Analysis and Views

ViewPoints: Fulcrum’s clinical pivot leaves investors guessing
Ref: ViewPoints Desk
Tags: ViewPointsFulcrum Therapeutics Clinical Research (R&D) Regulatory Affairslosmapimod
ViewPoints: Inovio vaccine prospects growing dimmer
Ref: ViewPoints Desk
Tags: ViewPointsInovioCOVID-19 Clinical Research (R&D) Corporate AffairsINO-4800
ViewPoints: AnaptysBio’s fading hopes of troubling Dupixent all but ECLIPSEd
Ref: ViewPoints Desk
Tags: ViewPointsAnaptysBio Regeneron Sanofi AstraZeneca GSKDermatitis FDAClinical Research (R&D)etokimab Dupixent MEDI3506 GSK3772847
ViewPoints: Roche’s investment in autoimmune diseases gets derailed
Ref: ViewPoints Desk
Tags: ViewPointsRoche Takeda PharmaceuticalsIBD Clinical Research (R&D)etrolizumab Entyvio
ViewPoints: Seres finally sees recurrent success
Ref: ViewPoints Desk
Tags: ViewPointsSeres TherapeuticsBacterial Infections IBD Clinical Research (R&D) Regulatory AffairsSER-109
ViewPoints: Bristol Myers Squibb’s search for re-energisation continues
Ref: ViewPoints Desk
Tags: ViewPointsBristol Myers Squibb FDACorporate Affairs Marketing & SalesBMS-986165 Opdivo Revlimid
ViewPoints: Roche targets Biogen with SMA pricing
Ref: ViewPoints Desk
Tags: ViewPointsRoche PTC Therapeutics Biogen NovartisSpinal Muscular Atrophy Marketing & Sales Regulatory AffairsEvrysdi Spinraza Zolgensma
ViewPoints: Denali scores a Biogen payday
Ref: ViewPoints Desk
Tags: ViewPointsDenali Therapeutics BiogenParkinson's Clinical Research (R&D) Corporate Affairs LicensingDNL151 DNL201
Friday Five - The pharma week in review (7 August 2020)
Ref: Friday Five Desk
Tags: Friday FiveAbbVie Biogen Denali Therapeutics Gilead Merck & Co. Novavax Regeneron Voyager Therapeutics FDA
ViewPoints: Regeneron keeps powering through the pandemic
Ref: ViewPoints Desk
Tags: ViewPointsRegeneron Sanofi FDAClinical Research (R&D) Corporate Affairs Marketing & SalesEylea Dupixent REGN-COV2